'Infliximab' presentation slideshows

Dr. X. Baraliakos Rheumazentrum Ruhrgebiet, Herne Ruhr-University Bochum Germany

Anti-TNF therapy in ankylosing spondylitis - Clinical and structural outcomes -. Dr. X. Baraliakos Rheumazentrum Ruhrgebiet, Herne Ruhr-University Bochum Germany. Ankylosing spondylitis: a chronic inflammatory rheumatic disease leading to high clinical impairment. 24 years.

957 views • 74 slides

481 views • 35 slides

653 views • 32 slides

Literature Review

Literature Review. Peter R. McNally, DO, FACP, FACG University Colorado School of Medicine Center for Human Simulation Aurora, Colorado 80045. Sunanda Kane, MD, 1 Bahar Khatibi B Sc 2 & Deepa Reddy, MD 1. Higher Incidence of Abnormal Pap Smears in Women

534 views • 26 slides

When Should We Stop Anti-TNF Therapy and How Do We Then Treat the Patient?

356 views • 24 slides

Case #2 Biologics and Pregnancy

332 views • 22 slides

Unexplained Visual Loss

Unexplained Visual Loss. Laura S. Gilmore, MD Grand Rounds September 9, 2005 Texas Tech University HSC Lubbock, TX Discussant: Kenn Freedman, MD. History. Chief Complaint: Vision loss, OD>OS

554 views • 15 slides

Adalimumab: Lymphomas

Presented at the Arthritis Advisory Committee meeting on March 4, 2003 by Jeffrey N. Siegel, M.D. Adalimumab: Lymphomas. Controlled portions of controlled trials: Adalimumab: 2 cases among 1380 patients, 0.6 yrs mean exposure Placebo: 0 cases among 690 patients, 0.5 yrs mean exposure

205 views • 9 slides

EXPRESS: Response Rates at Week 10

126 views • 4 slides

EXPRESS: Response Rates at Week 10

44 views • 4 slides